4.2 Article

Matrix Metalloproteinase-Induced Epithelial-Mesenchymal Transition in Breast Cancer

期刊

出版社

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10911-010-9177-x

关键词

MMP; EMT; Mammary development; Breast cancer; TIMP; Protease inhibitors

资金

  1. National Cancer Institute [CA122086, CA128660, CA132879]
  2. James and Esther King Foundation [07KN09, 08KN12]
  3. Bankhead-Coley Foundation [09BB17]
  4. Susan B. Komen foundation [FAS0703855]
  5. National Institutes of Health [CA116201]

向作者/读者索取更多资源

Matrix metalloproteinases (MMPs) degrade and modify the extracellular matrix (ECM) as well as cell-ECM and cell-cell contacts, facilitating detachment of epithelial cells from the surrounding tissue. MMPs play key functions in embryonic development and mammary gland branching morphogenesis, but they are also upregulated in breast cancer, where they stimulate tumorigenesis, cancer cell invasion and metastasis. MMPs have been investigated as potential targets for cancer therapy, but clinical trials using broad-spectrum MMP inhibitors yielded disappointing results, due in part to lack of specificity toward individual MMPs and specific stages of tumor development. Epithelial-mesenchymal transition (EMT) is a developmental process in which epithelial cells take on the characteristics of invasive mesenchymal cells, and activation of EMT has been implicated in tumor progression. Recent findings have implicated MMPs as promoters and mediators of developmental and pathogenic EMT processes in the breast. In this review, we will summarize recent studies showing how MMPs activate EMT in mammary gland development and in breast cancer, and how MMPs mediate breast cancer cell motility, invasion, and EMT-driven breast cancer progression. We also suggest approaches to inhibit these MMP-mediated malignant processes for therapeutic benefit.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据